Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| DNTH | PRESS-RELEASE | bullish | 8/10 | Dianthus Therapeutics reported full-year 2025 financial results and announced a positive GO decision in the Phase 3 CAPT | Mar 9, 2026 |
| RLMD | PRESS-RELEASE | neutral | 6/10 | Relmada Therapeutics announced a $160 million PIPE financing through the sale of common stock and pre-funded warrants, w | Mar 9, 2026 |
| NBP | PRESS-RELEASE | bullish | 8/10 | NovaBridge Biosciences announced positive topline Phase 2a results for VIS-101, a dual VEGF-A X ANG-2 inhibitor, showing | Mar 9, 2026 |
| CSTL | PRESS-RELEASE | bullish | 7/10 | Castle Biosciences announced new prospective, multicenter study data showing that its DecisionDx-Melanoma test, via the | Mar 9, 2026 |
| SPRY | PRESS-RELEASE | mixed | 6/10 | ARS Pharmaceuticals reported full-year 2025 revenue of $84.3 million, driven by $72.2 million in U.S. net product revenu | Mar 9, 2026 |
| DYN | PRESS-RELEASE | bullish | 8/10 | Dyne Therapeutics announced 24-month data from its Phase 1/2 DELIVER trial showing sustained functional improvements in | Mar 8, 2026 |
| DNTH | PRESS-RELEASE | neutral | 5/10 | Dianthus Therapeutics announced a conference call to discuss interim responder analysis results from Part A of the Phase | Mar 8, 2026 |
| AIM | PRESS-RELEASE | neutral | 4/10 | AIM ImmunoTech Inc. closed a $1.8 million rights offering, issuing units consisting of Series G Convertible Preferred St | Mar 6, 2026 |
| LSTA | PRESS-RELEASE | bullish | 8/10 | Lisata Therapeutics (LSTA) has agreed to be acquired by private company Kuva Labs in a deal valuing each share at $5.00 | Mar 6, 2026 |
| NTLA | PRESS-RELEASE | neutral | 3/10 | Intellia Therapeutics granted inducement awards of 16,500 RSUs to six new employees outside its shareholder-approved equ | Mar 6, 2026 |
| LNTH | PRESS-RELEASE | neutral | 5/10 | Lantheus Holdings received FDA approval for PYLARIFY TruVu, a new formulation of its leading PSMA PET imaging agent for | Mar 6, 2026 |
| BBOT | PRESS-RELEASE | bullish | 8/10 | BBOT announced preclinical and early clinical data for BBO-11818, a novel panKRAS inhibitor showing potent activity agai | Mar 6, 2026 |
| SLDB | PRESS-RELEASE | neutral | 6/10 | Solid Biosciences (SLDB) announced a $240 million private placement through the sale of common stock and pre-funded warr | Mar 6, 2026 |
| DAWN | PRESS-RELEASE | bullish | 9/10 | Servier has agreed to acquire Day One Biopharmaceuticals (DAWN) for $21.50 per share in cash, representing a total equit | Mar 6, 2026 |
| ADIL | PRESS-RELEASE | mixed | 6/10 | Adial Pharmaceuticals reported its 2025 fiscal year financial results, highlighting a reduced net loss of $8.0M (from $1 | Mar 6, 2026 |
| PMVP | PRESS-RELEASE | mixed | 6/10 | PMV Pharmaceuticals reported financial results for 2025, highlighted by advancing its lead drug rezatapopt in the Phase | Mar 6, 2026 |
| ALLR | PRESS-RELEASE | bullish | 7/10 | Allarity Therapeutics has closed a $20 million non-convertible debt financing with Streeterville Capital, extending its | Mar 6, 2026 |
| IMRX | PRESS-RELEASE | bullish | 8/10 | Immuneering reported strong clinical data from its Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer | Mar 6, 2026 |
| ATAI | PRESS-RELEASE | mixed | 6/10 | AtaiBeckley Inc. reported its Q4 and full-year 2025 financial results, highlighted by a successful FDA End-of-Phase 2 me | Mar 6, 2026 |
| JBIO | PRESS-RELEASE | mixed | 6/10 | Jade Biosciences reported its full-year 2025 financial results, highlighting a strong cash position of $336.2 million fo | Mar 6, 2026 |
| CLDI | PRESS-RELEASE | neutral | 4/10 | Calidi Biotherapeutics (CLDI) announced a proposed underwritten public offering of units consisting of common stock (or | Mar 5, 2026 |
| MEOH | PRESS-RELEASE | bearish | 6/10 | Methanex reported a Q4 2025 net loss of $89 million, driven by an $82 million non-cash impairment charge related to its | Mar 5, 2026 |
| MDWD | PRESS-RELEASE | neutral | 3/10 | MediWound Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, disclosing audited fina | Mar 5, 2026 |
| KYTX | PRESS-RELEASE | bullish | 8/10 | Kyverna Therapeutics announced selected presentations at the 2026 American Academy of Neurology (AAN) Annual Meeting, in | Mar 5, 2026 |
| TNXP | PRESS-RELEASE | bullish | 8/10 | Tonix Pharmaceuticals announced the publication of pharmacokinetic data supporting TONMYA (cyclobenzaprine HCl sublingua | Mar 5, 2026 |
| BBOT | PRESS-RELEASE | bullish | 8/10 | BBOT, a clinical-stage oncology company, reported its fourth quarter and full year 2025 financial results alongside posi | Mar 5, 2026 |
| CRBU | PRESS-RELEASE | mixed | 6/10 | Caribou Biosciences reported fourth quarter and full-year 2025 financial results, highlighting clinical progress in its | Mar 5, 2026 |
| MGX | PRESS-RELEASE | mixed | 6/10 | Metagenomi Therapeutics (MGX) reported its full-year 2025 financial results, highlighted by a significant reduction in R | Mar 5, 2026 |
| NXTC | PRESS-RELEASE | neutral | 5/10 | NextCure provided a business update and reported full-year 2025 financial results, highlighting anticipated clinical dat | Mar 5, 2026 |
| AVIR | PRESS-RELEASE | mixed | 6/10 | Atea Pharmaceuticals reported financial results for Q4 and full year 2025, showing increased R&D spend due to its Phase | Mar 5, 2026 |